1. Home
  2. KPLT vs AYTU Comparison

KPLT vs AYTU Comparison

Compare KPLT & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Katapult Holdings Inc.

KPLT

Katapult Holdings Inc.

HOLD

Current Price

$5.89

Market Cap

30.7M

ML Signal

HOLD

Logo Aytu BioPharma Inc.

AYTU

Aytu BioPharma Inc.

HOLD

Current Price

$2.67

Market Cap

25.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KPLT
AYTU
Founded
2012
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.7M
25.7M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
KPLT
AYTU
Price
$5.89
$2.67
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$10.00
$9.33
AVG Volume (30 Days)
19.2K
59.3K
Earning Date
01-01-0001
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$27,632,080.00
Revenue This Year
$21.42
N/A
Revenue Next Year
$15.48
$44.11
P/E Ratio
N/A
N/A
Revenue Growth
N/A
277.47
52 Week Low
$5.50
$0.95
52 Week High
$24.15
$3.07

Technical Indicators

Market Signals
Indicator
KPLT
AYTU
Relative Strength Index (RSI) 36.50 63.73
Support Level $5.50 $2.14
Resistance Level $6.92 $2.82
Average True Range (ATR) 0.34 0.13
MACD -0.05 0.05
Stochastic Oscillator 18.13 96.43

Price Performance

Historical Comparison
KPLT
AYTU

About KPLT Katapult Holdings Inc.

Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

Share on Social Networks: